Neuroscience

Cognition-Enhancer Pharmaceuticals: Foresight Report

Here is the Executive Summary of the newly released Foresight report on cognition enhancers:

Executive Summary

"The search for treatments for dementia, alongside other scientific and societal changes, has prompted the development of symptomatic treatments and disease-modifying drugs for people with degenerative brain diseases, mild cognitive impairment, and psychiatric diseases that involve cognition impairment. The enhancement of aspects of cognition, such as learning and memory, now seems possible for people with normal age-related decline and in healthy people, although so far the effects of these cognition enhancers are modest. The next two decades are likely to bring deeper knowledge of the mechanisms of learning, memory, and forgetting, together with an understanding of the relationship between changes in molecules, cells and brain circuits, and changes in cognition. Already, research efforts by the pharmaceutical industry are poised to deliver many more disease modifiers and putative cognition enhancers, though limitations exist in translating laboratory findings into effective interventions for human use.

"If effective interventions become available, their general use will bring health, social, ethical and regulatory issues. The widespread use of cognition enhancers for healthy people could have substantial impact and potentially become problematic – a minority may have abuse liability. Mechanisms do not exist currently to regulate cognition enhancers for non-medical purposes, though social changes together with commercial pressures mean that their use for enhancement is likely to be increasingly required, desired and accepted. Their use for disease-related impairments seems unlikely to cause concerns if cost-effective treatments are used to enhance function and quality of life. New challenges will include the development of biomarkers to allow early intervention and the targeting of therapies for the best effect on the individual."

The full report can be accessed at Cognition Enhancers.
-
Anthony H. Risser | neuroscience | neuropsychology | brain

- The Special Issue Spotter
We trawl the world's journals so you don't have to: Extended mind (Cognitive Systems Research). From the editorial: 'The extended mind literature cuts across a bewildering smorgasbord of (often overlapping) and even incompatible ... research...

- Would You Take A Pill To Boost Your Brain Power?
Is there any difference between drinking coffee to pep yourself up and taking a drug like Modafinil, which has been shown to increase alertness, planning and memory? There could be side effects and if everyone else in your office or class was popping...

- The Special Issue Spotter
Approaches to identifying students with specific learning difficulties. (Psychology In The Schools). Mental representations of attachment. (Attachment and Human Development). Inhibition of return (we're slower to return our gaze to the same place...

- Neuropsychology Abstract Of The Day: Alzheimer's Disease
Does pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease relieve caregiver burden? Drugs Aging. 2012 Mar 1;29(3):167-179 Levy K, Lanctôt KL, Farber SB, Li A, Herrmann NAbstractCaregiving for patients with Alzheimer's...

- Neuropsychology Abstract Of The Day: Assessment Of Social Cognition In Tbi
An active area of test development and research in contemporary clinical neuropsychology: Social Cognition Impairments in Relation to General Cognitive Deficits, Injury Severity and Prefrontal Lesions in Traumatic Brain Injury Patients. Journal of Neurotrauma....

Neuroscience